Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Open in API
Filings indexed 1,216 across all filing types
Latest filing 2025-04-07 Regulatory Filings
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 7, 2025. It reports the entry into a material definitive agreement, specifically a Settlement Agreement related to patent infringement litigation. The document includes detailed descriptions of the settlement terms, licensing agreements, and payment arrangements. It also references a press release attached as an exhibit. The Form 8-K is a regulatory filing used to report major events that shareholders should know about, such as material agreements. This document is not an annual or quarterly report, audit report, earnings release, or any other financial report type. It is a regulatory announcement of a material event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (6578 characters) and content confirm it is a full report, not just a brief announcement or certification.
2025-04-07 English
8-K
Governance Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 12, 2025. The key content is the approval and adoption of the Third Amended and Restated Bylaws by the Board of Directors, reflecting a change in voting standards for director elections. There is no financial data or earnings information, nor is it an annual or quarterly report. The focus is on governance changes, specifically amendments to the company's bylaws. This fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3829 characters, which is sufficient to contain substantive information rather than just an announcement. Therefore, the classification is CGR with high confidence.
2025-03-14 English
DEFA14A
Remuneration Information Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or soliciting material related to shareholder voting matters, specifically director nominations for the upcoming Annual Meeting. It includes detailed information about the solicitation of proxies, director nominations, and related corporate governance matters. It is not an annual report, earnings release, or other financial report but rather a proxy solicitation document. The presence of the SEC form name 'DEFA14A' and references to the proxy statement and solicitation confirm this classification. Therefore, the document fits the Remuneration Information (DEF 14A) category, which covers reports detailing compensation and proxy solicitation materials related to directors and executives.
2025-03-14 English
Proxy Solicitation & Information Statement 2025
Proxy Solicitation & Information Statement
2025-03-14 English
Regulatory Filings 2025
Regulatory Filings
2025-03-06 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Pacira BioSciences, Inc. It registers additional shares of common stock under an inducement plan. The document includes legal and procedural information related to the registration of securities, references prior registration statements, and contains signatures and consents. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length (8281 characters) and content confirm it is not a brief announcement but a full registration statement, which is a regulatory filing type.
2025-02-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.